UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abstract 4823: Alvocidib enhances the efficacy of cytarabine and daunorubicin (7+3) in non-clinical models of acute myeloid leukemia

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4823-4823

2018

Volltextzugriff (PDF)

DNA structure: Visualizing the quadruplex

Nature chemistry, 2013-03, Vol.5 (3), p.153

2013

Volltextzugriff (PDF)

Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3804-3804

2019

Volltextzugriff (PDF)

Abstract B178: Targeting Myc in triple-negative breast cancer models through the dual inhibition of PIM kinases and CDK9

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B178-B178

2018

Volltextzugriff (PDF)

Abstract B024: PKM2 activation suppresses cellular ROS scavenging capacity and potentiates doxorubicin antitumor activity

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B024-B024

2018

Volltextzugriff (PDF)

Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization

Bioorganic & medicinal chemistry letters, 2018-03, Vol.28 (5), p.934-941

2018

Volltextzugriff (PDF)

Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C081-C081

2019

Volltextzugriff (PDF)

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Blood, 2017-12, Vol.130 (Suppl_1), p.937-937

2017

Volltextzugriff (PDF)

Visualizing the quadruplex

Nature chemistry, 2013-02, Vol.5 (3), p.153-155

2013

Volltextzugriff (PDF)

Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5133-5133

2017

Volltextzugriff (PDF)

Abstract 883: Alvocidib-mediated inhibition of CDK9 upregulates BIM via suppression of miR17-92

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.883-883

2018

Volltextzugriff (PDF)

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

Blood, 2016-12, Vol.128 (22), p.263-263

2016

Volltextzugriff (PDF)

Abstract 1106: Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1106-1106

2017

Volltextzugriff (PDF)

Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.235-235

2016

Volltextzugriff (PDF)

Abstract 3728: Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3728-3728

2016

Volltextzugriff (PDF)

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Blood, 2015-12, Vol.126 (23), p.273-273

2015

Volltextzugriff (PDF)

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

Blood, 2015-12, Vol.126 (23), p.3253-3253

2015

Volltextzugriff (PDF)

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Blood, 2016-12, Vol.128 (22), p.1652-1652

2016

Volltextzugriff (PDF)

7-(4 H-1,2,4-Triazol-3-yl)benzo[ c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity

Bioorganic & medicinal chemistry letters, 2011-11, Vol.21 (22), p.6687-6692

2011

Volltextzugriff (PDF)

Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms

Bioorganic & medicinal chemistry letters, 2017-09, Vol.27 (17), p.3992-4000

2017

Volltextzugriff (PDF)

Abstract 3604: Targeting the PIM kinases in combination with BTK inhibition is synergistic in preclinical models of B-cell malignancies

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3604-3604

2015

Volltextzugriff (PDF)

Abstract 2698: Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2698-2698

2015

Volltextzugriff (PDF)

Abstract C202: CDK9 inhibition synergizes with BRD4 inhibitor-mediated super enhancer transcriptional repression in multiple preclinical tumor models

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C202-C202

2015

Volltextzugriff (PDF)

An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7062-7062

2015

Volltextzugriff (PDF)

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Blood, 2015-12, Vol.126 (23), p.1343-1343

2015

Volltextzugriff (PDF)

26 – 50 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(63)

Sprache

Englisch
(63)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Humans
(20)
Life Sciences & Biomedicine
(20)
Cell Line, Tumor
(13)
Animals
(11)
Biological And Medical Sciences
(10)
Casein Kinase Ii - Antagonists & Inhibitors
(10)
Chemistry
(10)
Chemistry, Medicinal
(10)
Mice
(10)
Pharmacology & Pharmacy
(10)
Oncology
(9)
Physical Sciences
(9)
Medical Sciences
(8)
Naphthyridines - Pharmacology
(8)
Antineoplastic Agents - Pharmacology
(7)
Neoplasms - Drug Therapy
(7)
Pharmacology. Drug Treatments
(7)
Structure-Activity Relationship
(7)
Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract 4823: Alvocidib enhances the efficacy of cytarabine and daunorubicin (7+3) in non-clinical models of acute myeloid leukemia

DNA structure: Visualizing the quadruplex

Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer

Abstract B178: Targeting Myc in triple-negative breast cancer models through the dual inhibition of PIM kinases and CDK9

Abstract B024: PKM2 activation suppresses cellular ROS scavenging capacity and potentiates doxorubicin antitumor activity

Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization

Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Visualizing the quadruplex

Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

Abstract 883: Alvocidib-mediated inhibition of CDK9 upregulates BIM via suppression of miR17-92

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

Abstract 1106: Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma

Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies

Abstract 3728: Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

7-(4 H-1,2,4-Triazol-3-yl)benzo[ c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity

Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms

Abstract 3604: Targeting the PIM kinases in combination with BTK inhibition is synergistic in preclinical models of B-cell malignancies

Abstract 2698: Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia

Abstract C202: CDK9 inhibition synergizes with BRD4 inhibitor-mediated super enhancer transcriptional repression in multiple preclinical tumor models

An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Suchergebnisse filtern